Non-Small Cell Lung Cancer

Why trials studying Non-Small Cell Lung Cancer stopped, in this sample of ClinicalTrials.gov.

27 stopped trials with a clear reason; 85% ended for non-scientific reasons.

Trials

• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
  NCT05358249 · TERMINATED · funding or business
  “Business reasons and not based on any safety concerns.”
• A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
  NCT05275673 · TERMINATED · funding or business
  “Sponsor decision - funding issues”
• Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
  NCT05400577 · WITHDRAWN · slow enrollment
  “Grantor withdrew support due to slow accrual”
• A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
  NCT04430933 · WITHDRAWN · funding or business
  “Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.”
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  NCT04984811 · TERMINATED · funding or business
  “sponsor decision (not for safety)”
• FL-101 in Surgically Resectable Non-Small Cell Lung Cancer
  NCT04758949 · WITHDRAWN · funding or business
  “Sponsor Decision”
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
  NCT04849273 · TERMINATED · safety
  “Adverse change in the risk/benefit.”
• Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy
  NCT04037462 · TERMINATED · slow enrollment
  “Low accrual”
• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
  NCT04892017 · TERMINATED · funding or business
  “Trial terminated due to business decision, not based on any safety or efficacy concerns.”
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
  NCT03770299 · WITHDRAWN · funding or business
  “Business objectives have changed”
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04027946 · TERMINATED · slow enrollment
  “Study was terminated due to slow accrual.”
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
  NCT03447769 · TERMINATED · other
  “Upon review of the primary analysis results, the benefit-risk was assessed by the Steering Committee Members with the decision that the study will be closed. No new safety signals were observed for canakinumab.”
• A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
  NCT03048136 · WITHDRAWN · funding or business
  “Business objective has changed”
• Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
  NCT03138889 · TERMINATED · funding or business
  “Sponsor decision”
• Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
  NCT02538432 · WITHDRAWN · staffing, sites or logistics
  “PI No Longer at University of Maryland. Now at Fox Chase”
• Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
  NCT03091491 · TERMINATED · slow enrollment
  “Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative therapy and clinician's choice to put patient on immunotherapy outside of trial setting.”
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
  NCT02669914 · TERMINATED · funding or business
  “Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice”
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
  NCT02468661 · TERMINATED · slow enrollment
  “Major challenge for enrollment of participants.”
• Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
  NCT02431169 · TERMINATED · slow enrollment
  “Low accrual”
• Pazopanib in Molecularly Selected Patients With Advanced NSCLC
  NCT02193152 · TERMINATED · funding or business
  “Terminated by sponsor”
• A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
  NCT02309892 · TERMINATED · slow enrollment
  “Slow enrolment - standard of care evolved over the duration of the study such that treatment regimen employed in the study was no longer current standard of care for first line resulting in recruitment challenges.”
• Safety Study of SEA-CD40 in Cancer Patients
  NCT02376699 · TERMINATED · funding or business
  “Study closed due to portfolio prioritization”
• Common Safety Follow-up Trial of Tecemotide (L-BLP25)
  NCT01423760 · TERMINATED · funding or business
  “The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.”
• Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
  NCT01212627 · TERMINATED · funding or business
  “Determination to stop enrollment made due to funding”
• Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
  NCT00862134 · TERMINATED · futility
  “Interim analysis indicated low probability of clinically significant result”
• A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
  NCT00404703 · TERMINATED · safety
  “Primary (safety) endpoint reached”
• Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
  NCT00351039 · TERMINATED · slow enrollment
  “slow accrual”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.